119 related articles for article (PubMed ID: 22139648)
1. Treatment Patterns of Bone-targeting Agents Among Solid Tumor Patients With Bone Metastases: An Analysis of Electronic Health Record Data in the United States From 2014 to 2018.
Nicholson G; Carlson KB; Hernandez RK; Schenfeld J; Cadieux B; Henry D; De Sousa Barbosa VJ; Saad H
Am J Clin Oncol; 2024 Apr; 47(4):177-184. PubMed ID: 38200688
[TBL] [Abstract][Full Text] [Related]
2. Bone-Targeted Therapy Regimen and Skeletal-Related Events in Patients Surviving Longer Than 2 Years With Metastatic Breast Cancer and Bone Metastasis.
Jayan A; Raghavendra AS; Bassett R; Barcenas CH
Clin Breast Cancer; 2023 Dec; 23(8):e515-e522. PubMed ID: 37735019
[TBL] [Abstract][Full Text] [Related]
3. Cinobufotalin Capsule Combined with Zoledronic Acid in the Treatment of Pain Symptoms and Clinical Efficacy in Prostate Cancer Patients with Bone Metastases: A Retrospective Study.
Zhang F; Dong Y; Chen F; Niu M; Liu Z; Wang C
Arch Esp Urol; 2024 Apr; 77(3):242-248. PubMed ID: 38715164
[TBL] [Abstract][Full Text] [Related]
4. Bone-targeting agents in major solid tumour metastases: a multinational cohort study.
Kim JH; Shen CY; Au PC; Baek YH; Cheung CL; Chung WP; Kleinman NJ; Lam TC; Liao TC; Lin TC; Shin JY; Sing CW; Wong ICK; Lai EC
BMJ Support Palliat Care; 2024 Jan; 13(e3):e1064-e1073. PubMed ID: 35177433
[TBL] [Abstract][Full Text] [Related]
5. Management of bone health in patients with cancer: a survey of specialist nurses.
Drudge-Coates L; van Muilekom E; de la Torre-Montero JC; Leonard K; van Oostwaard M; Niepel D; Jensen BT
Support Care Cancer; 2020 Mar; 28(3):1151-1162. PubMed ID: 31203509
[TBL] [Abstract][Full Text] [Related]
6. Characteristic features and prognostic factors in gastric cancer patients with bone metastases: multicenter experience.
Hamdard J; Bilici A; Sakin A; Kahraman S; Yasin AI; Kalaci E; Gokmen I; Acikgoz O; Kutlu Y; Sendur MAN; Olmez OF; Seker M
J Chemother; 2024 May; ():1-10. PubMed ID: 38803194
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial to compare the efficacy of bisphosphonates in the management of painful bone metastasis.
Choudhury KB; Mallik C; Sharma S; Choudhury DB; Maiti S; Roy C
Indian J Palliat Care; 2011 Sep; 17(3):210-8. PubMed ID: 22346045
[TBL] [Abstract][Full Text] [Related]
8. Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies.
Yamamoto Y; Yamashiro H; Schneeweiss A; Müller V; Gluz O; Klare P; Aktas B; Magdolna D; Büdi L; Pikó B; Mangel L; Toi M; Morita S; Ohno S
Breast Cancer; 2023 Jan; 30(1):88-100. PubMed ID: 36057014
[TBL] [Abstract][Full Text] [Related]
9. Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study.
Yamamoto Y; Yamashiro H; Toh U; Kondo N; Nakamura R; Kashiwaba M; Takahashi M; Tsugawa K; Ishikawa T; Nakayama T; Ohtani S; Takano T; Fujisawa T; Toyama T; Kawaguchi H; Mashino K; Tanino Y; Morita S; Toi M; Ohno S
Breast Cancer; 2021 Jan; 28(1):145-160. PubMed ID: 32715420
[TBL] [Abstract][Full Text] [Related]
10. Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy.
Signore A; Lauri C; Auletta S; Varani M; Onofrio L; Glaudemans AWJM; Panzuto F; Marchetti P
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32218303
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer.
Ueno NT; Tahara RK; Fujii T; Reuben JM; Gao H; Saigal B; Lucci A; Iwase T; Ibrahim NK; Damodaran S; Shen Y; Liu DD; Hortobagyi GN; Tripathy D; Lim B; Chasen BA
Cancer Med; 2020 Feb; 9(3):1025-1032. PubMed ID: 31849202
[TBL] [Abstract][Full Text] [Related]
12. Multimodal imaging of bone metastases: From preclinical to clinical applications.
Ellmann S; Beck M; Kuwert T; Uder M; Bäuerle T
J Orthop Translat; 2015 Oct; 3(4):166-177. PubMed ID: 30035055
[TBL] [Abstract][Full Text] [Related]
13. Stathmin is involved in the cooperative effect of Zoledronic acid and gefitinib on bone homing breast cancer cells in vitro.
Oda M; Iwaya K; Kikuchi R; Kobayashi T; Yoneda T; Nishikawa K; Matsubara O; Kohno N
J Bone Oncol; 2012 Sep; 1(2):40-6. PubMed ID: 26909254
[TBL] [Abstract][Full Text] [Related]
14. Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategy.
Fontanella C; Fanotto V; Rihawi K; Aprile G; Puglisi F
Clin Exp Metastasis; 2015 Dec; 32(8):819-33. PubMed ID: 26343511
[TBL] [Abstract][Full Text] [Related]
15. M1 stage subdivision and treatment outcome of patients with bone-only metastasis of nasopharyngeal carcinoma.
Shen L; Dong J; Li S; Wang Y; Dong A; Shu W; Wu M; Pan C; Xia Y; Wu P
Oncologist; 2015 Mar; 20(3):291-8. PubMed ID: 25660157
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the attenuation of breast cancer bone metastasis in mice by zoledronic acid using (99m)Tc bone scintigraphy.
Wu C; Yang S; Sun Z; Han X; Ye Y; Liu S
Pathol Oncol Res; 2014 Jul; 20(3):747-54. PubMed ID: 24610002
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for patients with bone-only metastasis in breast cancer.
Ahn SG; Lee HM; Cho SH; Lee SA; Hwang SH; Jeong J; Lee HD
Yonsei Med J; 2013 Sep; 54(5):1168-77. PubMed ID: 23918566
[TBL] [Abstract][Full Text] [Related]
18. Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases.
Niikura N; Liu J; Hayashi N; Palla SL; Tokuda Y; Hortobagyi GN; Ueno NT; Theriault RL
Cancer; 2012 Apr; 118(8):2039-47. PubMed ID: 22139648
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid.
Zhao X; Xu X; Zhang Q; Jia Z; Sun S; Zhang J; Wang B; Wang Z; Hu X
BMC Cancer; 2011 Sep; 11():403. PubMed ID: 21936956
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
